{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:09:56Z","timestamp":1792706996323,"version":"4.5.0"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Targeted therapies directed against ERBB2 are the cornerstone of medical treatment for ERBB2-positive breast cancers but are contraindicated during pregnancy.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To describe the association of exposure to anti-ERBB2 agents during pregnancy with pregnancy and fetal or newborn outcomes, and to compare the risk and types of adverse outcomes reported more frequently in this context than after exposure to other anticancer agents.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>For this case-control study, All reports with a pregnancy-related condition and an antineoplastic agent (Anatomical Therapeutic Chemical classification group L01) registered in the World Health Organization international pharmacovigilance database VigiBase up to June 26, 2022, were extracted. All reports with a pregnancy, an antineoplastic treatment during pregnancy, and a cancer were retained. Reports with anticancer agents prescribed for nononcologic purposes were not included.<\/jats:p><\/jats:sec>Exposure<\/jats:title>The exposure group was defined as reports that mention anti-ERBB2 agents compared with exposure to other anticancer agents.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>The main outcome was the reporting odds ratio (ROR) for maternofetal complications in the group exposed to anti-ERBB2 agents compared with other anticancer agents, as determined using a disproportionality analysis.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 3558 reports (anti-ERBB2 agents, 328; other anticancer agents, 3230) were included in the analysis. In the group exposed to anti-ERBB2 agents, most reports were from the US (159 [48.5%]), the mean (SD) age of participants was 30.8 (10.4) years, and 209 patients (97.7%) were treated for breast cancers. The molecules most frequently involved in cases with anti-ERBB2 agents were trastuzumab (n\u2009=\u2009302), pertuzumab (n\u2009=\u200955), trastuzumab-emtansine (n\u2009=\u200920), and lapatinib (n\u2009=\u200918). The outcomes overreported in these cases included oligohydramnios (ROR, 17.68 [95% CI, 12.26-25.52]; P<\/jats:italic>\u2009&amp;lt;\u2009.001), congenital respiratory tract disorders (ROR, 9.98 [95% CI, 2.88-34.67]; P<\/jats:italic>\u2009&amp;lt;\u2009.001), and neonatal kidney failure (ROR, 9.15 [95% CI, 4.62-18.12]; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Sensitivity and multivariable analyses found similar results. Toxic effects were also significantly overreported for trastuzumab-emtansine (cardiovascular malformation: ROR, 4.46 [95% CI, 1.02-19.52]) and lapatinib (intrauterine growth restriction: ROR, 7.68 [95% CI, 3.01-19.59]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this case-control study of 328 individuals exposed to anti-ERBB2 agents during pregnancy, exposure was associated with a severe specific adverse pregnancy and fetal or newborn outcomes compared with exposure to other anticancer treatments.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.39934","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:32:34Z","timestamp":1698334354000},"page":"e2339934","source":"Crossref","is-referenced-by-count":22,"title":["Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns"],"prefix":"10.1001","volume":"6","author":[{"given":"Paul","family":"Gougis","sequence":"first","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Medical Oncology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"Sorbonne Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Assistance Publique\u2013H\u00f4pitaux de Paris, Clinical Investigation Center (CIC-1901), Department of Pharmacology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grandal","sequence":"additional","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Jochum","sequence":"additional","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Gynecology, Strasbourg University Hospital, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bihan","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Assistance Publique\u2013H\u00f4pitaux de Paris, Clinical Investigation Center (CIC-1901), Department of Pharmacology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Coussy","sequence":"additional","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Barraud","sequence":"additional","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Asselain","sequence":"additional","affiliation":[{"name":"Department of Statistics, Association de Recherche sur les Cancers dont Gyn\u00e9cologiques\u2013Groupe d\u2019Investigateurs National des Etudes des Cancers Ovariens et du sein (ARCAGY-GINECO), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Dumas","sequence":"additional","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Sebbag","sequence":"additional","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judicael","family":"Hotton","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Institut Godinot, Reims, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Spaggiari","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Maternal-Fetal Medicine, Assistance Publique\u2013H\u00f4pitaux de Paris, Necker Enfants-Malades Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eblle","family":"Savarino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enora","family":"Laas","sequence":"additional","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, UMRS 1136, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Reyal","sequence":"additional","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Surgical Oncology, Institut Godinot, Reims, France"},{"name":"Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hamy","sequence":"additional","affiliation":[{"name":"Residual Tumor & Response to Treatment Laboratory, RT2Lab, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U932 Immunity and Cancer, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"},{"name":"Department of Medical Oncology, Institut Curie, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"3","key":"zoi231165r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"zoi231165r2","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1001\/jamaoncol.2015.2413","article-title":"Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients.","volume":"1","author":"Loibl","year":"2015","journal-title":"JAMA Oncol"},{"key":"zoi231165r3","doi-asserted-by":"publisher","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi231165r4","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.3390\/cancers12123616","article-title":"Update on the management of breast cancer during pregnancy.","volume":"12","author":"Poggio","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"zoi231165r5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/s12885-021-08162-3","article-title":"Trastuzumab administration during pregnancy: an update.","volume":"21","author":"Andrikopoulou","year":"2021","journal-title":"BMC Cancer"},{"issue":"5","key":"zoi231165r6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR Database System: basic facts.","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"issue":"38","key":"zoi231165r7","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"zoi231165r8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00038-2020","article-title":"Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis.","volume":"55","author":"Moey","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"zoi231165r10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3390\/cancers15010173","article-title":"Immune checkpoint inhibitors and pregnancy: analysis of the VigiBase Spontaneous Reporting System.","volume":"15","author":"Noseda","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"zoi231165r11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.therap.2020.02.022","article-title":"Uses of pharmacovigilance databases: an overview.","volume":"75","author":"Bihan","year":"2020","journal-title":"Therapie"},{"issue":"2","key":"zoi231165r12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10549-012-2368-y","article-title":"Trastuzumab administration during pregnancy: a systematic review and meta-analysis.","volume":"137","author":"Zagouri","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"zoi231165r13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1097\/CAD.0000000000000658","article-title":"Use of pertuzumab and trastuzumab during pregnancy.","volume":"29","author":"Yildirim","year":"2018","journal-title":"Anticancer Drugs"},{"issue":"23","key":"zoi231165r14","doi-asserted-by":"publisher","first-page":"8498","DOI":"10.1073\/pnas.84.23.8498","article-title":"Stage- and tissue-specific expression of the neu oncogene in rat development.","volume":"84","author":"Kokai","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"zoi231165r15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4103\/2249-4847.101705","article-title":"Potter\u2019s sequence.","volume":"1","author":"Shastry","year":"2012","journal-title":"J Clin Neonatol"},{"issue":"6555","key":"zoi231165r16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development.","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"issue":"2","key":"zoi231165r17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11523-009-0112-2","article-title":"Cardiac toxicity with anti\u2013HER-2 therapies: what have we learned so far?","volume":"4","author":"de Azambuja","year":"2009","journal-title":"Target Oncol"},{"issue":"2","key":"zoi231165r18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case\u2013non-case studies: principle, methods, bias and interpretation.","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"zoi231165r9","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): product- or population-specific considerations, III: pregnant and breastfeeding women. Published online 2019. Accessed August 8, 2022. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-good-pharmacovigilance-practices-product-population-specific-considerations-iii_en.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2811107\/gougis_2023_oi_231165_1697661701.64706.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:32:37Z","timestamp":1698334357000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2811107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.39934","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}